Psychedelic Medicine

Association

Psilocybin in pharmacotherapy of obsessive-compulsive disorder

Excerpts from the publication

Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD’s etiology, current treatment options, and the emerging evidence supporting psilocybin’s efficacy in managing OCD symptoms.

Read more

Drug–drug interactions involving classic psychedelics: A systematic review

Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches

The effect of ketamine on preventing postpartum depression

Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression